ReviewInternational urology and nephrology2026
Efficacy and safety of non-steroidal mineralocorticoid receptor antagonist and SGLT2 inhibitor combination therapy versus SGLT2-inhibitor monotherapy in patients with chronic kidney disease with albuminuria: a systematic review and meta-analysis of randomized controlled trials.
Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) exert complementary renoprotective effects in chronic kidney disease (CKD). However, the efficacy and safety of nsMRA plus SGLT2 inhibitor combination therapy compared with SGLT2 inhibitor monotherapy in patients with albuminuria remain uncertain.
methodsWe systematically searched for randomized controlled trials (RCTs) comparing nsMRA plus SGLT2 inhibitor therapy with SGLT2 inhibitor monotherapy in adults with CKD with albuminuria. Outcomes included changes in albumin-creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), serum potassium, categorical ACR response (≥ 30% and ≥ 50% reduction), and short- and long-term safety outcomes, including hyperkalemia, adverse events (AEs), and serious adverse events (SAEs). Random-effects models were used to pool ratio of means (ROM), mean differences (MD), and risk ratios (RR).
resultsFour RCTs including 1835 patients were analyzed. Combination therapy was associated with a greater reduction in ACR compared with monotherapy (ROM = 0.67, 95% CI 0.63-0.72), corresponding to an approximate 33% reduction. The likelihood of achieving ≥ 30% (RR = 1.36) and ≥ 50% (RR = 1.76) ACR reduction was significantly higher with combination therapy, however, with a modest increase in serum potassium (MD = 0.11 mmol/L) and a significantly higher risk of hyperkalemia both short term (RR = 1.55) and long-term. There was no overall effect on eGFR, the risk of AEs and SAEs were comparable.
conclusionIn patients with CKD with albuminuria, nsMRA plus SGLT2 inhibitor therapy may provide clinically meaningful albuminuria reduction, however with an increased risk of hyperkalemia. Given reliance on surrogate endpoints, heterogeneity and limited long-term data, these findings should be interpreted cautiously and require confirmation in larger, long-term clinical outcome trials.
Indexed as
Identifiers
42154418What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.